Treatment of Locally Advanced Resectable Adenocarcinoma of the Oesophagus and Oesophagogastric Junction
This protocol addresses the management of patients with locally advanced, resectable adenocarcinoma of the oesophagus and oesophagogastric junction (OGJ) — a clinical setting in which surgical resectability is established and multimodal treatment is indicated.
Clinical scenario
Patients present with locally advanced resectable adenocarcinoma of the oesophagus and OGJ. Preoperative chemoradiotherapy (CRT) can be recommended as one standard of care in this setting, based on established trial evidence.
Treatment approach
For patients who have undergone neoadjuvant chemoradiotherapy and surgical resection and have evidence of residual pathological disease in the resection specimen, the protocol specifies an adjuvant immunotherapy-based approach as the next treatment step.
Full eligibility criteria, regimen details, and evidence grading are available in the complete structured protocol.
References
- Based on the results of CROSS, preoperative CRT can be recommended as one standard of care for locally advanced AC of the oesophagus and OGJ.
- Patients with SCC or AC of the oesophagus including OGJ cancer who have undergone neoadjuvant CRT and show evidence of residual pathological disease in the resection specimen (ypT1 and/or ypN1) should be treated with adjuvant nivolumab [I, A; ESMO-MCBS v1.1 score: A].
DOI: 10.1016/j.annonc.2022.07.003
View source ↗